These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 15959774

  • 1. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites.
    Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL.
    Cancer Immunol Immunother; 2005 Nov; 54(11):1072-81. PubMed ID: 15959774
    [Abstract] [Full Text] [Related]

  • 2. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
    Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4345-54. PubMed ID: 17671115
    [Abstract] [Full Text] [Related]

  • 3. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
    van Beek AA, Zhou G, Doukas M, Boor PPC, Noordam L, Mancham S, Campos Carrascosa L, van der Heide-Mulder M, Polak WG, Ijzermans JNM, Pan Q, Heirman C, Mahne A, Bucktrout SL, Bruno MJ, Sprengers D, Kwekkeboom J.
    Int J Cancer; 2019 Aug 15; 145(4):1111-1124. PubMed ID: 30719701
    [Abstract] [Full Text] [Related]

  • 4. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
    Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN, Appella E, DeLeo AB, Whiteside TL.
    Cancer Res; 2002 Jun 15; 62(12):3521-9. PubMed ID: 12067999
    [Abstract] [Full Text] [Related]

  • 5. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.
    Sakakura K, Chikamatsu K, Furuya N, Appella E, Whiteside TL, Deleo AB.
    Clin Immunol; 2007 Oct 15; 125(1):43-51. PubMed ID: 17631051
    [Abstract] [Full Text] [Related]

  • 6. CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.
    Andrade Filho PA, Ito D, Deleo AB, Ferris RL.
    Cancer Immunol Immunother; 2010 Oct 15; 59(10):1561-8. PubMed ID: 20577877
    [Abstract] [Full Text] [Related]

  • 7. p53 as an immunotherapeutic target in head and neck cancer.
    Hoffmann TK, Bier H, Donnenberg AD, Whiteside TL, De Leo AB.
    Adv Otorhinolaryngol; 2005 Oct 15; 62():151-60. PubMed ID: 15608425
    [Abstract] [Full Text] [Related]

  • 8. Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer.
    Strauss L, Bergmann C, Whiteside TL.
    Int J Cancer; 2007 Dec 01; 121(11):2473-83. PubMed ID: 17691114
    [Abstract] [Full Text] [Related]

  • 9. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells.
    Hilchey SP, De A, Rimsza LM, Bankert RB, Bernstein SH.
    J Immunol; 2007 Apr 01; 178(7):4051-61. PubMed ID: 17371959
    [Abstract] [Full Text] [Related]

  • 10. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP, Hermonat PL.
    Gynecol Oncol; 2001 Jun 01; 81(3):424-32. PubMed ID: 11371133
    [Abstract] [Full Text] [Related]

  • 11. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.
    Schuler PJ, Schilling B, Harasymczuk M, Hoffmann TK, Johnson J, Lang S, Whiteside TL.
    Eur J Immunol; 2012 Jul 01; 42(7):1876-85. PubMed ID: 22585562
    [Abstract] [Full Text] [Related]

  • 12. Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
    Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL.
    Clin Cancer Res; 2014 May 01; 20(9):2433-44. PubMed ID: 24583792
    [Abstract] [Full Text] [Related]

  • 13. CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.
    Chikamatsu K, Sakakura K, Takahashi G, Okamoto A, Furuya N, Whiteside TL, DeLeo AB, Masuyama K.
    Cancer Immunol Immunother; 2009 Sep 01; 58(9):1441-8. PubMed ID: 19184003
    [Abstract] [Full Text] [Related]

  • 14. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A, Schlößer H, Rothschild SI, Thelen M, Reuter S, Zentis P, Shimabukuro-Vornhagen A, Theurich S, Wennhold K, Garcia-Marquez M, Tharun L, Quaas A, Schauss A, Isensee J, Hucho T, Huebbers C, von Bergwelt-Baildon M, Beutner D.
    Oncotarget; 2017 Jul 04; 8(27):44418-44433. PubMed ID: 28574843
    [Abstract] [Full Text] [Related]

  • 15. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M.
    Cancer; 1994 Aug 15; 74(4):1275-82. PubMed ID: 7914469
    [Abstract] [Full Text] [Related]

  • 16. CD4+ T helper responses in squamous cell carcinoma of the head and neck.
    Chikamatsu K, Sakakura K, Yamamoto T, Furuya N, Whiteside TL, Masuyama K.
    Oral Oncol; 2008 Sep 15; 44(9):870-7. PubMed ID: 18221909
    [Abstract] [Full Text] [Related]

  • 17. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
    Ito D, Visus C, Hoffmann TK, Balz V, Bier H, Appella E, Whiteside TL, Ferris RL, DeLeo AB.
    Int J Cancer; 2007 Jun 15; 120(12):2618-24. PubMed ID: 17294448
    [Abstract] [Full Text] [Related]

  • 18. GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T Cells.
    Rakké YS, Campos Carrascosa L, van Beek AA, de Ruiter V, van Gemerden RS, Doukas M, Doornebosch PG, Vermaas M, Ter Borg S, van der Harst E, Coene PPLO, Kliffen M, Grünhagen DJ, Verhoef C, IJzermans JNM, Kwekkeboom J, Sprengers D.
    Cell Mol Gastroenterol Hepatol; 2023 Jun 15; 15(1):77-97. PubMed ID: 36155259
    [Abstract] [Full Text] [Related]

  • 19. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
    Cicinnati VR, Zhang X, Yu Z, Ferencik S, Schmitz KJ, Dworacki G, Kaczmarek E, Oldhafer K, Frilling A, Baba HA, Schmid KW, Grosse-Wilde H, Broelsch CE, DeLeo AB, Gerken G, Beckebaum S.
    Int J Cancer; 2006 Dec 15; 119(12):2851-60. PubMed ID: 16998881
    [Abstract] [Full Text] [Related]

  • 20. Regulatory T-cell expansion and function do not account for the impaired alloreactivity of ex vivo-expanded T cells.
    Montcuquet N, Mercier-Letondal P, Perruche S, Duperrier A, Couturier M, Bouchekioua A, Bonyhadi M, Ferrand C, Tiberghien P, Robinet E.
    Immunology; 2008 Nov 15; 125(3):320-30. PubMed ID: 18445006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.